Where cancer genomics should go next: A clinician's perspective

Human Molecular Genetics

Volumn 23, Issue R1, 2014, Pages

  Rafii, A ^a,b,c   Touboul, C ^a,d   Al Thani, H ^a   Suhre, K ^a,e   Malek, J A ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c HÔPITAL ARNAUD DE VILLENEUVE   (France)

^d Hôpital Lariboisière   (France)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53;

CARCINOGENESIS; CLINICAL TRIAL (TOPIC); GENETICS; GENOMICS; HUMAN; HUMAN GENOME; MUTATION; NEOPLASM; PERSONALIZED MEDICINE; PROCEDURES;

CARCINOGENESIS; CLINICAL TRIALS AS TOPIC; GENOME, HUMAN; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84906836267     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu234     Document Type: Review

References (53)

1. Trainer, A.H., Lewis, C.R., Tucker, K., Meiser, B., Friedlander, M. and Ward, R.L. (2010) The role of BRCAmutation testing in determining breast cancer therapy. Nat. Rev. Clin. Oncol., 7, 708-717.
2. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G. et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl. J. Med., 350, 2129-2139.
3. Rexer, B.N. and Arteaga, C.L. (2013) Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications. Cancer Res., 73, 3817-3820.
4. Arnedos, M., Vielh, P., Soria, J.C. and Andre, F. (2014) The genetic complexity of common cancers and the promise of personalized medicine: is there any hope? J. Pathol., 232, 274-282.
5. Simon, R. and Roychowdhury, S. (2013) Implementing personalized cancer genomics in clinical trials. Nat. Rev. Drug Discov., 12, 358-369.
6. Prat, A., Ellis, M.J. and Perou, C.M. (2012) Practical implications of gene-expression-based assays for breast oncologists. Nat. Rev. Clin. Oncol., 9, 48-57.
7. Burrell, R.A., McGranahan, N., Bartek, J. and Swanton, C. (2013) The causes and consequences of genetic heterogeneity in cancer evolution. Nature, 501, 338-345.
8. Umetani, N., Giuliano, A.E., Hiramatsu, S.H., Amersi, F., Nakagawa, T., Martino, S. and Hoon, D.S. (2006) Prediction of breast tumor progression by integrity of free circulating DNA in serum. J. Clin. Oncol., 24, 4270-4276.
9. Schwarzenbach, H., Eichelser, C., Kropidlowski, J., Janni, W., Rack, B. and Pantel, K. (2012) Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression. Clin. Cancer Res., 18, 5719-5730.
10. Der Auwera, I., Elst, H.J.,Van Laere, S.J., Maes, H., Huget, P., van Dam, P., Van Marck, E.A., Vermeulen, P.B. and Dirix, L.Y. (2009) The presence of circulating totalDNAand methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br. J. Cancer, 100, 1277-1286.
11. Sakurai, M. and Sandberg, A.A. (1973) Prognosis of acute myeloblastic leukemia: chromosomal correlation. Blood, 41, 93-104.
12. Fitzgerald, P.H., Crossen, P.E. and Hamer, J.W. (1973) Abnormal karyotypic clones in human acute leukemia: their nature and clinical significance. Cancer, 31, 1069-1077.
13. Sakurai, M. and Sandberg, A.A. (1976) Chromosomes and causation of human cancer and leukemia. XI. Correlation of karyotypes with clinical features of acute myeloblastic leukemia. Cancer, 37, 285-299.
14. Macconaill, L.E. and Garraway, L.A. (2010) Clinical implications of the cancer genome. J. Clin. Oncol., 28, 5219-5228.
15. Pearson, M. and Rowley, J.D. (1985) The relation of oncogenesis and cytogenetics in leukemia and lymphoma. Annu. Rev. Med., 36, 471-483.
16. Kreso, A., O'Brien, C.A., van Galen, P., Gan, O.I., Notta, F., Brown, A.M., Ng, K., Ma, J., Wienholds, E., Dunant, C. et al. (2013) Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science, 339, 543-548.
17. Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P. et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New Engl. J. Med., 366, 883-892.
18. Bashashati, A., Ha, G., Tone, A., Ding, J., Prentice, L.M., Roth, A., Rosner, J., Shumansky, K., Kalloger, S., Senz, J. et al. (2013) Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J. Pathol., 231, 21-34.
19. Lis, R., Touboul, C., Halabi, N.M., Madduri, A.S., Querleu, D., Mezey, J., Malek, J.A., Suhre, K. and Rafii, A. (2014) Mesenchymal cell interaction with ovarian cancer cells induces a background dependent pro-metastatic transcriptomic profile. J. Trans. Med., 12, 59.
20. Malek, J.A., Mery, E., Mahmoud, Y.A., Al-Azwani, E.K., Roger, L., Huang, R., Jouve, E., Lis, R., Thiery, J.P., Querleu, D. et al. (2011) Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasis. PLoS ONE, 6, e28561.
21. Gibney, G.T., Messina, J.L., Fedorenko, I.V., Sondak, V.K. and Smalley, K.S. (2013) Paradoxical oncogenesis-the long-term effects of BRAF inhibition in melanoma. Nat. Rev. Clin. Oncol., 10, 390-399.
22. Kwong, L.N., Costello, J.C., Liu, H., Jiang, S., Helms, T.L., Langsdorf, A.E., Jakubosky, D., Genovese, G., Muller, F.L., Jeong, J.H. et al. (2012) Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat. Med., 18, 1503-1510.
23. Chin, L., Andersen, J.N. and Futreal, P.A. (2011) Cancer genomics: from discovery science to personalized medicine. Nat. Med., 17, 297-303.
24. Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S. et al. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol., 26, 5705-5712.
25. Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R.L., Bardelli, A. and Bernards, R. (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature, 483, 100-103.
26. Demetri, G.D., von Mehren, M., Blanke, C.D., Den Abbeele, A.D., Eisenberg, B., Roberts, P.J., Heinrich, M.C., Tuveson, D.A., Singer, S., Janicek, M. et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.NewEngl. J. Med., 347, 472-480.
27. Goldman, J.M. and Melo, J.V. (2003) Chronic myeloid leukemia-advances in biology and new approaches to treatment. New Engl. J. Med., 349, 1451-1464.
28. Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S.,Zimmermann, J. and Lydon, N.B. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 2, 561-566.
29. Becker, J.C., Brocker, E.B., Schadendorf, D. and Ugurel, S. (2007) Imatinib in melanoma: a selective treatment option based on KIT mutation status? J. Clin. Oncol., 25, e9.
30. Hodi, F.S., Friedlander, P., Corless, C.L., Heinrich, M.C., Mac Rae, S., Kruse, A., Jagannathan, J., Den Abbeele, A.D., Velazquez, E.F., Demetri, G.D. et al. (2008) Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol., 26, 2046-2051.
31. International Cancer Genome, C., Hudson, T.J., Anderson, W., Artez, A., Barker, A.D., Bell, C., Bernabe, R.R., Bhan, M.K., Calvo, F., Eerola, I. et al. (2010) International network of cancer genome projects. Nature, 464, 993-998.
32. Ledford, H. (2010) Big science: the cancer genome challenge. Nature, 464, 972-974.
33. Cancer Genome Atlas Research, N. (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455, 1061-1068.
34. Brosens, R.P., Haan, J.C., Carvalho, B., Rustenburg, F., Grabsch, H., Quirke, P., Engel, A.F., Cuesta, M.A., Maughan, N., Flens, M. et al. (2010) Candidate driver genes in focal chromosomal aberrations of stage II colon cancer. J. Pathol., 221, 411-424.
35. Cancer Genome Atlas Research, N. (2011) Integrated genomic analyses of ovarian carcinoma. Nature, 474, 609-615.
36. Kang, J., D'Andrea, A.D. and Kozono, D. (2012) A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J. Natl Cancer Inst., 104, 670-681.
37. Yoshihara, K., Tsunoda, T., Shigemizu, D., Fujiwara, H., Hatae, M., Fujiwara, H., Masuzaki, H., Katabuchi, H., Kawakami, Y., Okamoto, A. et al. (2012) High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin. Cancer Res., 18, 1374-1385.
38. Yang, J.Y., Yoshihara, K., Tanaka, K., Hatae, M., Masuzaki, H. and Itamochi, H., Cancer Genome Atlas Research Network, Takano, M., Ushijima, K., Tanyi, J.L. et al. (2013) Predicting time to ovarian carcinoma recurrence using protein markers. J. Clin. Invest., 123, 3740-3750.
39. Johnatty, S.E., Beesley, J., Gao, B., Chen, X., Lu, Y., Law, M.H., Henderson, M.J., Russell, A.J., Hedditch, E.L., Emmanuel, C. et al. (2013) ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol. Oncol., 131, 8-14.
40. Cancer Genome Atlas, N. (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature, 487, 330-337.
41. Vaske, C.J., Benz, S.C., Sanborn, J.Z., Earl, D., Szeto, C., Zhu, J., Haussler, D. and Stuart, J.M. (2010) Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics, 26, i237-i245.
42. Cancer Genome Atlas Research, N. (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature, 489, 519-525.
43. Cancer Genome Atlas Network. (2012) Comprehensive molecular portraits of human breast tumours. Nature, 490, 61-70.
44. Cancer Genome Atlas Research NetworkKandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., Shen, H., Robertson, A.G., Pashtan, I., Shen, R. et al. (2013) Integrated genomic characterization of endometrial carcinoma. Nature, 497, 67-73.
45. Kandoth, C., McLellan, M.D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J.F., Wyczalkowski, M.A. et al. (2013) Mutational landscape andsignificance across12major cancer types. Nature,502,333-339.
46. Cancer Genome Atlas Research Network. (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature, 499, 43-49.
47. Cancer Genome Atlas Research Network. (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature, 507, 315-322.
48. Iyer, G., Al-Ahmadie, H., Schultz, N., Hanrahan, A.J., Ostrovnaya, I., Balar, A.V., Kim, P.H., Lin, O., Weinhold, N., Sander, C. et al. (2013) Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J. Clin. Oncol., 31, 3133-3140.
49. Tsimberidou, A.M., Iskander, N.G., Hong, D.S., Wheler, J.J., Falchook, G.S., Fu, S., Piha-Paul, S., Naing, A., Janku, F., Luthra, R. et al. (2012) Personalized medicine in a phase I clinical trials program: theMDAnderson Cancer Center initiative. Clin. Cancer Res., 18, 6373-6383.
50. Hollebecque, A., Massard, C., De Baere, T., Auger, N., Lacroix, L., Koubi-Pick, N., Vielh, P., Lazar, V., Bahleda, R., Ngo-camus, M. et al. (2013) Molecular screening for cancer treatment optimization (MOSCATO 01): A prospective molecular triage trial-Interim results. J. Clin. Oncol., 31(Suppl), abstr 2512.
51. Andre, F., Bachelot, T., Commo, F., Campone, M., Arnedos, M., Dieras, V., Lacroix-Triki, M., Lacroix, L., Cohen, P., Gentien, D. et al. (2014) Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol., 15, 267-274.
52. Von Hoff, D.D., Stephenson, J.J. Jr, Rosen, P., Loesch, D.M., Borad, M.J., Anthony, S., Jameson, G., Brown, S., Cantafio, N., Richards, D.A. et al. (2010) Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J. Clin. Oncol., 28, 4877-4883.
53. Iyer, G., Hanrahan, A.J., Milowsky, M.I., Al-Ahmadie, H., Scott, S.N., Janakiraman, M., Pirun, M., Sander, C., Socci, N.D., Ostrovnaya, I. et al. (2012) Genome sequencing identifies a basis for everolimus sensitivity. Science, 338, 221.